Leios Therapeutics clears FDA end-of-phase 2 meeting for 10XB-101
Leios Therapeutics has announced a positive end-of-phase 2 meeting with the US Food and Drug Administration for 10XB-101, its investigational injectable treatment for moderate-to-severe submental fat fullness in adults. The meeting produced alignment on the key elements of a pivotal programme, giving the California-based company a defined regulatory route toward a potential new drug application.
The FDA confirmed it will accept either a single adequately powered pivotal trial or two Phase 3 studies, offering Leios meaningful flexibility in its development planning. Regulators also agreed on a Phase 3 dose of up to 4%, primary and secondary efficacy endpoints, and the total number of patient exposures required to support a safety database adequate for a 505(b)(2) NDA submission. The 505(b)(2) pathway allows an applicant to reference existing safety and efficacy data for a known active ingredient, which may reduce the overall development burden compared with a full 505(b)(1) route.
Chief executive Ted White said the outcome provides "a clear path to Phase 3 and to registration," and cited progress in manufacturing and intellectual property alongside the regulatory news.
Licensing and IP foundations
The EoP2 result is the latest in a series of milestones Leios has recorded during 2026. The company has already closed exclusive regional licensing and strategic investment agreements with BNC Korea and affiliates of China Medical System Holdings Limited, covering South Korea and China respectively. Under those arrangements, development costs in each licensed territory are borne by the regional partner. Leios describes the two markets as the largest aesthetic medicine markets outside the United States, giving the company leveraged exposure to significant international demand without carrying the full capital cost of local development.
On the intellectual property side, Leios has filed applications in two additional patent families that, if granted, would extend protection for 10XB-101 through 2044 and 2047, a runway that could support a meaningful period of commercial exclusivity post-approval.
Market context and competitive landscape
The injectable aesthetic market is well-established and increasingly competitive. Allergan's deoxycholic acid product Kybella, approved by the FDA in 2015 for submental fat reduction, is the best-known precedent in this specific indication, though uptake plateaued as clinicians gravitated toward alternative body-contouring modalities including cryolipolysis devices and external ultrasound. Leios is positioning 10XB-101 as a best-in-class alternative, differentiated by its use of polidocanol, a synthetic non-ionic detergent with an established safety record in sclerotherapy applications. The company says the compound induces targeted adipolysis by disrupting fat cell membranes before the cellular debris is cleared by the body's natural processes.
The 505(b)(2) approach is well-suited to a known active ingredient with an existing regulatory dossier, and FDA's acceptance of a single pivotal trial option could compress the timeline to submission relative to a conventional two-study requirement. Investors will be focused on when Leios intends to initiate Phase 3, the capital requirements to get there, and whether any additional regional partnerships are planned to further offset development costs.